icon-    folder.gif   Conference Reports for NATAP  
 
  17th CROI
Conference on Retroviruses
and Opportunistic Infections
San Francisco CA
February 16-19, 2010
Back grey_arrow_rt.gif
 
 
 
The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster
 
 
  Reported by Jules Levin
CROI SF 2010 Feb 16-19
 
Calvin Cohen1, David Shamblaw2, Peter Ruane3, Richard Elion4, Edwin DeJesus5, HuiC. Liu6, LijieZhong6, David Warren6, Brian P. Kearney6, and Steven L. Chuck6
 
1Community Research Initiative of New England, Boston, MA; 2San Diego, CA; 3Los Angeles, CA; 4Whitman Walker Clinic, Washington, D.C.; 5Orlando Immunology Center, Orlando, FL; and 6Gilead Sciences, Foster City,

image002.gif

image004.gif

image006.gif

image008.gif

image010.gif

image012.gif

image014.gif

image016.gif

image018.gif

image020.gif

image022.gif

image024.gif

image026.gif

image028.gif

image030.gif

image032.gif